课题基金 / 基金详情

Development of AD214 a novel anti-fibrotic treatment for advanced Age related macular degeneration

Development of AD214 a novel anti-fibrotic treatment for advanced Age related macular degeneration
AD214的开发,一种治疗晚期年龄相关性黄斑变性的新型抗纤维化疗法
批准号:
nhmrc : 2000044
负责人:
金额:
$68.8万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Development Grants
财政年份:
2021
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2021-01-01 至 2023-12-31

项目摘要

项目成果

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Age related macular degeneration remains the leading cause of blindness in this and other industrialised countries. Although treatment is available for an advanced form of the disease, many do not respond, or lose significant amounts of vision with long term treatment. This proposal will provide critical data for commericalizing a novel therapy called an i-body (AD214), that reduces vision loss in this disease by blocking the formation of scarring with reduced need for injections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文